Medullary Cystic Disease Medication

Updated: Mar 16, 2020
  • Author: Prasad Devarajan, MD, FAAP; Chief Editor: Craig B Langman, MD  more...
  • Print

Medication Summary

Pharmacotherapy in patients with nephronophthisis (NPH)–medullary cystic kidney disease (MCKD) is symptomatic and directed at preventing and treating complications of progressive renal insufficiency.



Class Summary

This is a glycoprotein normally produced in the kidneys that is responsible for the stimulation of red blood cell production. Anemia occurs because of deficient erythropoietin production during renal failure.

Epoetin alfa (Epogen, Procrit)

Indicated for the treatment of anemia associated with chronic renal failure. Stimulates division and differentiation of committed erythroid progenitor cells; induces release of reticulocytes from bone marrow into bloodstream.